Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
Martin Reck(German Center for Lung Research), C. Manegold(University Medical Centre Mannheim), J. Mezger(Heidelberg University), Joachim von Pawel(Asklepios Fachkliniken München-Gauting), V. Gorbounova(Russian Cancer Research Center NN Blokhin), Vera Hirsh(McGill University Health Centre), N. B. Leighl(Princess Margaret Cancer Centre), Petr Zatloukal(Heidelberg University), Rodryg Ramlau(Poznan University of Medical Sciences), Norman C. Moore(Roche (Switzerland)), Venice Archer(AstraZeneca (United Kingdom))
Cited by 644
Related Papers
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
|New England Journal of Medicine|2018|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer
|Journal of Clinical Oncology|2008|3.2k
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations
|Journal of Clinical Oncology|2013|3.2k